Biocon Q2FY27 Results: Net Profit Drops 52% YoY Despite Steady Biopharma Gains
Biocon Ltd 路 Press Release 路 04 Nov 2026, 6:53 pm
Biocon Q2FY27 Results: Net Profit Drops 52% YoY Despite Steady Biopharma Gains Biocon reported Q2FY27 consolidated revenue from operations of Rs 4,389 crore, up 2% YoY, supported by a 5% YoY rise in Biopharma revenue to Rs 3,583 crore (Biosimilars +3% YoY to Rs 2,809 crore, Generics +10% YoY to Rs 774 crore). EBITDA declined 7% YoY to Rs 865 crore with margins contracting 200 bps to 20%. Reported net profit fell 52% YoY to Rs 41 crore. Strategic milestones included a ~$400 million, 10-year Pertuzumab partnership in Brazil and a global Genentech settlement for Pebrilzo庐.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 18 Nov 2026
- Press Release 路 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
